Michael Bateman, MD
Family Medicine · Tacoma, WANPI 1215900279
Payments from drug & device makers
Across 250 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mentor Worldwide LLC$558
- Amgen$371
- Lilly USA, LLC$304
- Novo Nordisk$304
- Pfizer$246
- AstraZeneca$243
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,80599%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mentor Worldwide LLC | 14 | $558 |
| Amgen(2 entities) | 32 | $371 |
| Lilly USA, LLC | 31 | $304 |
| Novo Nordisk | 33 | $304 |
| Pfizer | 21 | $246 |
| AstraZeneca | 12 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $228 |
| Boehringer Ingelheim | 13 | $198 |
| Johnson & Johnson | 10 | $191 |
| Merck | 18 | $183 |
| Tepha Inc | 2 | $171 |
| Daiichi Sankyo Inc. | 4 | $89 |
| Radius Health, Inc. | 4 | $83 |
| AbbVie(2 entities) | 4 | $67 |
| Bausch Health US, LLC | 3 | $65 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Astellas Pharma US Inc | 3 | $55 |
| Novartis | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Circassia Inc. | 2 | $33 |
| Alfasigma USA, Inc. | 1 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Nevro Corp. | 1 | $25 |
| Therapeuticsmd, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Vertex | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Seqirus USA Inc | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| BD | 1 | $16 |
| Neuronetics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,826 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 64 | $49,024 |
| XareltoRivaroxaban | 39 | $47,781 |
| OzempicSemaglutide | 16 | $26,373 |
| CreonLipase/Protease/Amylase | 14 | $24,420 |
| JardianceEmpagliflozin | 13 | $19,519 |
| TrulicityDulaglutide | 11 | $18,302 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $7,704 |
| MovantikNaloxegol Oxalate | 11 | $4,583 |
| Dexlansoprazole DrDexlansoprazole | 21 | $3,689 |
| Testosterone | 26 | $3,390 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,771 |
| Levothyroxine Sodium | 233 | $2,623 |
| Atorvastatin Calcium | 206 | $2,326 |
| Duloxetine Hcl | 59 | $2,241 |
| Omeprazole | 120 | $2,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $246 | $49,02464 claims |
| Johnson & JohnsonXarelto | $191 | $47,78139 claims |
| AbbVieCreon, Combigan, Synthroid | $67 | $28,25741 claims |
| Novo NordiskOzempic | $304 | $26,37316 claims |
| Boehringer IngelheimJardiance | $198 | $19,51913 claims |
| Lilly USA, LLCTrulicity | $304 | $18,30211 claims |
| Sanofi-aventis U.S. LLCLantus | $60 | $1,53813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Tacoma
- James RoscettiTacoma$184K
- Marse McNaughtonTacoma$24K
- Benjamin DyTacoma$15K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.